Nicholas Investment Partners LP Acquires New Holdings in United Therapeutics Corporation $UTHR

Nicholas Investment Partners LP bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,141 shares of the biotechnology company’s stock, valued at approximately $3,869,000.

A number of other hedge funds have also recently modified their holdings of UTHR. Torren Management LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics during the second quarter valued at approximately $30,000. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, Royal Bank Of Canada lowered their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $512.88 on Tuesday. The firm’s 50 day moving average price is $532.35 and its 200-day moving average price is $538.04. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The company has a market cap of $22.00 billion, a PE ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company posted $6.41 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $518.39, for a total value of $4,924,705.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $168,188,006.77. The trade was a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,075 shares of company stock worth $233,942,595 in the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.